Close Menu

NEW YORK – Molecular diagnostics company Biocartis reported on Thursday that it saw an expansion of its installed instruments base in the third quarter, with the US market representing 40 percent of new Idylla instrument placements.

The company also reported a 27 percent year-over-year increase in commercial cartridge volumes, predominantly driven by Europe and rest-of-world markets, and said the development of its liquid biopsy Idylla ctEGFR Mutation Assay during Q3 resulted in the test's launch on Oct. 25.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.